Side-by-side · Research reference

PEG-MGFvsProstamax

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED2/69 cited

BAnimal-MechanisticHUMAN-REVIEWED11/38 cited

PEG-MGF

IGF-1Ec Splice Variant · PEGylated

~2 hrHalf-life (PEG)

~7 minNative MGF t½

IGF-1EcSplice variant

SQ · Research Protocol

Prostamax

Khavinson Bioregulator · Tissue-Specific Peptide

0.05 ng/mLActive concentrationZakutskiĭ 2006

2.5×SCE frequency increaseDzhokhadze 2012

4 AAPeptide length

SQ · Protocol per Khavinson tradition

01Mechanism of Action

Parameter

PEG-MGF

Prostamax

Primary target

IGF-1 receptor on muscle satellite cells and myocytes

Chromatin in prostatic cells — pericentromeric heterochromatin regions

Pathway

IGF-1R → PI3K/Akt → mTOR activation → Satellite cell proliferation & myoblast fusion

Epigenetic modulation → heterochromatin decondensation → transcriptional derepressionDzhokhadze 2012

Downstream effect

Satellite cell activation, muscle fiber repair, localized hypertrophy signaling

Increased sister chromatid exchange, Ag-NOR activation, reduced C-heterochromatin condensation; tissue-specific regenerative stimulation in prostate organotypic culturesDzhokhadze 2012 Zakutskiĭ 2006

Feedback intact?

Partially bypassed — does not require hepatic IGF-1 synthesis

—

Origin

IGF-1Ec splice variant (exon 4–6) conjugated to polyethylene glycol for extended circulation

Synthetic tetrapeptide modeled on naturally occurring protein-derived bioregulators isolated between lysine-arginine motifs in long-lived speciesKhavinson 2017

Antibody development

Unknown — no long-term human immunogenicity data

—

02Dosage Protocols

Parameter

PEG-MGF

Prostamax

Research dose range

100–200 mcg

Extrapolated from animal models; no validated human protocols.

—

Frequency

Post-training or daily

Timing to match endogenous MGF pulse post-exercise.

—

Half-life

~2 hours (PEGylated)

Native MGF: ~7 min; PEGylation extends circulation.

—

Evidence basis

Animal / mechanistic

Animal / organotypic cultureZakutskiĭ 2006 Dzhokhadze 2012

No randomized controlled trials in humans.

Reconstitution

Sterile bacteriostatic water

Lyophilized form; store reconstituted at 2–8 °C.

—

PEG molecular weight

Typically 5–30 kDa

Higher MW = longer t½, greater steric hindrance.

—

Timing

Within 30–60 min post-training

Aligns with endogenous MGF window.

—

Effective concentration (in vitro)

—

0.05 ng/mLZakutskiĭ 2006

Organotypic culture model; demonstrated tissue-specific stimulation.

Human clinical dose

—

Not established

No published human trials; dosing extrapolated from Russian clinical tradition (not peer-reviewed).

Age groups studied

—

Young (3-week) and aged (18-month) rats; elderly humans (75–86 years) in vitroZakutskiĭ 2006 Dzhokhadze 2012

Duration

—

Not specified

Khavinson protocols typically 10–20 days per cycle; no long-term safety data.

03Metabolic / Fat Loss Evidence

Parameter

PEG-MGF

Prostamax

Primary target

Muscle tissue (satellite cells, myocytes) — not adipose-specific

—

Indirect metabolic effect

IGF-1 signaling may modulate insulin sensitivity and lipid metabolismRen 2015

Mechanism distinct from direct lipolytic peptides.

—

Body composition

Lean mass preservation / hypertrophy focus

—

Fat loss evidence

No direct human or animal RCT data for PEG-MGF-driven fat reduction

—

04Side Effects & Safety

Parameter

PEG-MGF

Prostamax

Injection site reaction

Erythema, induration (common with SQ peptides)

—

Hypoglycemia risk

IGF-1 axis activation can lower blood glucose

—

IGF-1R overstimulation

Theoretical risk of aberrant cell proliferation with chronic supraphysiological exposure

—

Fluid retention

Possible with IGF-1 pathway activation (dose-dependent)

—

PEG accumulation

Chronic high-dose PEGylated proteins may accumulate in tissues; clearance slower in renal impairment

—

Antibody formation

PEGylated proteins can elicit anti-PEG antibodies (neutralizing potential unknown)

—

Cancer risk

IGF-1 axis stimulation contraindicated in active malignancy

—

Human safety data

Absent — no published human trials for PEG-MGF

Absent — no published Phase 1/2/3 trials

Published adverse events

—

None reported in available literature

Genotoxicity signals

—

Increased sister chromatid exchange (SCE) — marker of DNA recombination/repair; unclear long-term implications

Metal ion interactions

—

Modulates Cu(II) and Cd(II) chromatin effects; unknown clinical relevance

Absolute Contraindications

PEG-MGF

·Active malignancy or history of cancer (IGF-1R proliferative signaling)
·Known hypersensitivity to PEGylated compounds
·Pregnancy / lactation (no reproductive toxicity data)

Prostamax

·Active prostate malignancy — epigenetic modulation effects unknown in cancer

Relative Contraindications

PEG-MGF

·Diabetes (monitor glucose closely)
·Renal impairment (PEG clearance reduced)
·Retinopathy (IGF-1 axis effects on vascular proliferation)

Prostamax

·History of prostate cancer — theoretical concern re: transcriptional activation
·Undiagnosed prostatic nodules or elevated PSA

05Administration Protocol

Parameter

PEG-MGF

Prostamax

1. Reconstitution

Add 1–2 mL bacteriostatic water to lyophilized vial. Swirl gently — do not shake. Solution should be clear to slightly opalescent.

Subcutaneous or intramuscular — per Khavinson bioregulator tradition. No published human pharmacokinetic data.

2. Injection site

Subcutaneous — abdomen or thigh. Rotate sites to avoid lipodystrophy. Avoid areas with scar tissue or active inflammation.

If lyophilised: reconstitute with sterile water per manufacturer protocol (not standardized in literature).

3. Timing

Post-training preferred (within 30–60 min) to align with endogenous MGF expression window. Alternatively, daily morning dose on non-training days.

Typically daily or every-other-day in Russian clinical tradition; duration 10–20 days per cycle.

4. Storage

Lyophilized: room temperature, light-protected, desiccated. Reconstituted: refrigerate 2–8 °C, use within 14–21 days.

No established biomarkers. Theoretical: PSA, prostate imaging, symptom scores (IPSS for BPH).

5. Needle

29–31G insulin syringe, 8–12 mm length. Pinch skin fold, insert at 45° angle for subcutaneous delivery.

All protocols derived from non-peer-reviewed Russian clinical practice; Western regulatory approval absent.

06Stack Synergy

PEG-MGF

+ BPC-157

Moderate

View BPC-157 →

BPC-157 promotes angiogenesis and tendon/ligament repair via VEGF and growth factor modulation, while PEG-MGF targets satellite cell activation and myocyte proliferation. Complementary pathways for comprehensive tissue repair post-injury or intensive training. BPC-157's systemic stability and oral bioavailability contrast with PEG-MGF's localized IGF-1R signaling.

PEG-MGF: 100–200 mcg SQ post-training
BPC-157: 250–500 mcg SQ or oral, twice daily
Duration: 4–6 weeks (injury-dependent)
Primary benefit: Accelerated muscle and connective tissue repair, enhanced recovery

+ TB-500

Strong

View TB-500 →

TB-500 (Thymosin Beta-4 fragment) upregulates actin polymerization, cell migration, and anti-inflammatory pathways, while PEG-MGF drives satellite cell proliferation via IGF-1R/mTOR. Synergistic for muscle regeneration: TB-500 mobilizes progenitor cells, PEG-MGF stimulates their differentiation into myocytes. Both have overlapping but distinct repair cascades.

PEG-MGF: 100–200 mcg SQ post-training
TB-500: 2–5 mg SQ, 2× per week (loading), then weekly
Timing: Stagger injections by 6–12 hours
Primary benefit: Maximal satellite cell recruitment and myogenic differentiation, injury repair

Prostamax

— no documented stacks